Trial Profile
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary) ; Telaglenastat (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Calithera Biosciences
- 23 Nov 2020 Status changed from suspended to discontinued.
- 07 May 2020 According to a Calithera Biosciences media release, the company expects enrollment to resume in the second quarter of 2020.
- 14 Apr 2020 Status changed from recruiting to suspended, according to a Calithera Biosciences media release.